Trials / Unknown
UnknownNCT00103766
Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion
Randomized Comparison of Two Dose and Frequency Regimens of Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 75 (planned)
- Sponsor
- O'Brien, Jeana D., MD, FACP, FCCP · Individual
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the benefit to patients with empyema or complicated parapneumonic effusion (CPE) using a daily versus twice daily Alteplase regimen of two different dose strategies compared with saline placebo.
Detailed description
This is a randomized, double-blind, placebo-controlled pilot study. Patients with empyema and complicated parapneumonic effusion who are felt to require fibrinolytic therapy will be considered for study enrollment. Enrolled patients will be randomized to one of five potential treatment arms (saline placebo, 4 mg once daily, 4 mg twice daily, 10 mg once daily, or 10 mg twice daily) in a double-blinded manner.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alteplase |
Timeline
- Start date
- 2004-10-01
- First posted
- 2005-02-15
- Last updated
- 2006-08-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00103766. Inclusion in this directory is not an endorsement.